Spots Global Cancer Trial Database for A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas
Official Title: A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
Study ID: NCT03893682
Interventions
Study Description
Brief Summary: This study is being done to evaluate the safety, tolerability and effectiveness of Oral CG-806 for the treatment of patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or Non-Hodgkin's Lymphomas who have failed or are intolerant to two or more lines of established therapy or for whom no other treatment options are available.
Detailed Description: This is a multicenter, open-label, Phase Ia/b dose escalation study of safety, pharmacodynamics, and pharmacokinetics of CG-806 in ascending cohorts (3+3 design) to determine the MTD or recommended dose in patients with relapsed or refractory CLL/SLL or Non-Hodgkin's Lymphoma patients. This is to be followed by a cohort expansion phase at the MTD or recommended oral dose.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of California Los Angeles, Los Angeles, California, United States
Pacific Cancer Care, Monterey, California, United States
Torrance Memorial Physician Network, Redondo Beach, California, United States
UCSD Moores Cancer Center, San Diego, California, United States
Sharp Clinical Oncology Research, San Diego, California, United States
Ridley-Tree Cancer Center, Santa Barbara, California, United States
St. Joseph Heritage Heathcare, Santa Rosa, California, United States
Rocky Mountain Cancer Centers, Aurora, Colorado, United States
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
Orlando Health, Orlando, Florida, United States
Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States
University of Maryland, Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
The Center for Cancer and Blood Disorders a division of American Oncology Partners of Maryland, PA, Bethesda, Maryland, United States
UMass Memorial Medical Center, Worcester, Massachusetts, United States
University of Michigan, Ann Arbor, Michigan, United States
Mayo Clinic Rochester, Rochester, Minnesota, United States
SCL Health, St. Vincent Frontier Cancer Center, Billings, Montana, United States
Morristown Medical Center, Morristown, New Jersey, United States
Manhattan Hematology Oncology, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Prisma Health - ITOR, Greenville, South Carolina, United States
Carolina Blood and Cancer Care Associates, Rock Hill, South Carolina, United States
Texas Oncology - Austin-Midtown, Austin, Texas, United States
Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
Texas Oncology - Fort Worth Cancer Center, Fort Worth, Texas, United States
University of Texas, M.D. Anderson Cancer Center, Houston, Texas, United States
University of Texas Health Science Center at San Antonio, Mays Cancer Center, San Antonio, Texas, United States
Texas Oncology - Tyler, Tyler, Texas, United States
Virginia Oncology Associates, Norfolk, Virginia, United States
Northwest Cancer Specialists, P.C. - Compass Oncology, Vancouver, Washington, United States
Contact Details
Name: Rafael Bejar, MD, PhD
Affiliation: Aptose Biosciences Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
